Executive Overview

At the terminal stages of chronic disease processes in companion animals, pain management rapidly transcends simplicity. Long before a pet reaches their final days, clinicians and caregivers frequently encounter a clinical picture dominated by central sensitization, medication tolerance, paradoxical intolerances, and maladaptive pain pathways.

As standard analgesics steadily escalate, the daily workload of caregiving intensifies, while behavioral changes and clinical indicators become increasingly ambiguous. Both owners and veterinary professionals struggle to determine whether pain is being adequately addressed or if standard interventions have exhausted their therapeutic utility.

In these complex, refractory cases, subanesthetic ketamine offers a distinctive clinical advantage: an opportunity to actively interrupt the pain cycle rather than merely suppress symptoms. When deployed thoughtfully within veterinary hospice and palliative care, ketamine serves as a powerful instrument. It enables clinicians to re-establish patient comfort, reassess a true clinical baseline, and recalibrate daily multimodal pain strategies with heightened precision.

Authored from the insights of leading veterinary palliative experts like Dr. Tyler Carmack, Director of Hospice and Palliative Care for Caring Pathways, this review examines how subanesthetic ketamine changes the landscape of end-of-life care for companion animals.

Detailed Chronology: The Evolution of Ketamine in Veterinary Medicine

To appreciate the modern application of subanesthetic ketamine in palliative care, it is necessary to examine how our understanding of the drug has evolved from an anesthetic agent to a targeted neuromodulator.

1. From Dissociative Anesthetic to Neuromodulatory Adjunct

For decades, ketamine was primarily recognized and utilized as a dissociative anesthetic agent administered at high doses to induce surgical unconsciousness. However, pharmacological research over the past thirty years revealed that at significantly lower—subanesthetic—doses, ketamine exhibits profound analgesic properties independent of systemic sedation. This realization shifted its standing from an operating room necessity to a versatile tool for managing acute perioperative pain.

2. The Recognition of "Wind-Up" and Central Sensitization

As veterinary pain medicine matured, researchers began investigating why certain patients experienced unrelenting pain despite high doses of traditional analgesics like nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids. The identification of central sensitization—often termed "wind-up"—explained that continuous nociceptive input could cause spinal cord neurons to become permanently hyperexcitable. Ketamine emerged as a logical countermeasure due to its specific antagonism of N-methyl-D-aspartate (NMDA) receptors, which drive this neurological amplification.

3. Transition to Acute Surgical and Palliative Studies

Throughout the 2000s and 2010s, clinical trials began validating ketamine’s efficacy as an adjunct in acute settings, such as forelimb amputations and ovariohysterectomies. Researchers noted that short-duration infusions produced analgesic effects extending well beyond the plasma half-life of the drug. This observation paved the way for its modern adaptation into chronic pain management, senior pet osteoarthritis models, and ultimately, outpatient veterinary palliative care protocols.

Supporting Context & Metrics: Decoding the Science of End-of-Life Pain

Why End-of-Life Pain is Neurologically Unique

Chronic pain fundamentally alters the architecture of the nervous system. In companion animals suffering from advanced cancer, degenerative joint disease, neuropathic conditions, or end-stage organ failure, continuous nociceptive input triggers a cascade of neuroplastic changes within the spinal cord and brain.

Neurons located in the dorsal horn of the spinal cord become hyperexcitable, causing the threshold for pain transmission to plummet. At this advanced stage, the peripheral source of pain may remain relatively stable, but the central nervous system itself becomes an autonomous generator of suffering.

This pathophysiology manifests as:

• Hyperalgesia: An exaggerated, intensely painful response to noxious stimuli.
• Allodynia: Severe pain elicited by stimuli that would typically be entirely benign or non-painful.

Standard analgesics—including NSAIDs, gabapentinoids, acetaminophen, and opioids—effectively blunt initial signaling pathways, but they frequently fail to correct the underlying central dysregulation driving the condition. This exact neurochemical bottleneck is where ketamine’s mechanism of action proves clinically transformative.

The NMDA Receptor Connection

Ketamine’s primary analgesic value lies in its non-competitive antagonism of the N-methyl-D-aspartate (NMDA) receptor. As foundational reviews by Pozzi, Muir, and Traverso in the Journal of the American Veterinary Medical Association outline, NMDA receptor activation is the principal driver of wind-up and central sensitization following sustained nociceptive input. Ketamine represents the most clinically viable strategy to disrupt this process.

By blocking NMDA receptor activation at subanesthetic doses, ketamine achieves several critical clinical goals:

• It halts the self-sustaining loop of spinal cord hyperexcitability.
• It reverses or diminishes established central sensitization.
• It restores patient responsiveness to previously failing analgesic protocols, overcoming medication tolerance.

Crucially, these benefits extend beyond simple pharmacokinetics. The neuroplastic alterations triggered by a single intervention can shift pain processing trajectories far beyond the drug’s plasma half-life, creating what palliative clinicians describe as a therapeutic "neuroplastic window."

Key Clinical Research and Metrics

The evidence base supporting subanesthetic ketamine as an analgesic adjunct has expanded substantially:

• Wagner et al. (Canine Amputation Model): A prospective, randomized, blinded clinical trial involving 27 dogs undergoing forelimb amputation demonstrated that dogs receiving low-dose ketamine via constant rate infusion (CRI) exhibited significantly lower pain scores at 12 and 18 hours postoperatively. They were also meaningfully more active by the third postoperative day compared to control groups.
• Slingsby and Waterman-Pearson: Research confirmed that perioperative ketamine administration reduced rescue analgesia requirements in dogs undergoing routine surgeries, with preoperative groups maintaining consistently lower pain scores throughout observation windows.
• Ambros et al. (Feline Responses): Evaluations in conscious cats yielded more nuanced findings, showing modest effects on thermal and mechanical nociceptive thresholds at specific CRI rates, highlighting the absolute necessity of species-specific dosing strategies.
• The 2025 Cornell University Retrospective Case Series: Evaluating outpatient IV ketamine-lidocaine (KL) infusions in 114 animals (105 dogs, 9 cats) with refractory oncologic pain (primarily osteosarcoma), results showed that 76 percent of animals demonstrated marked clinical improvement in at least one key sign—most notably activity level, lameness, and owner-perceived comfort—following a single 4-to-6-hour infusion. Efficacy was notably tied to infusion rates ($ge 2$ $mu$g/kg/min) and total doses ($ge 0.5$ mg/kg), proving that ultralow dosing can sometimes undertreat central sensitization.
• Fry, Rychel, Tearney, and Guedes (Senior Chronic Pain): Enrolling 10 senior dogs with refractory osteoarthritis, cervical radiculopathy, or intervertebral disc disease, this trial administered serial IV ketamine infusions over a structured timeline. Blinded veterinary pain scores and owner-reported Canine Brief Pain Inventory (CBPI) metrics decreased significantly and sustained improvement through day 57, confirming durable neuroplastic relief.

Official Perspectives & Clinical Insights

Integrating advanced pharmacological interventions into home-based hospice environments requires a shift in clinical philosophy. Veterinary specialists emphasize that ketamine should not be viewed merely as an emergency rescue medication for hospitalized patients in crisis. Instead, it is an elegant, proactive component of a comprehensive palliative care plan.

The Clinical "Reset" Opportunity

According to expert veterinary practitioners like Dr. Tyler Carmack, one of the most underappreciated utilities of ketamine in hospice medicine is its capacity to serve as a diagnostic and therapeutic "reset."

After weeks or months of continuously escalating medication doses for a patient with refractory pain, discerning how much diminished quality of life stems from disease progression versus central nervous system signal amplification becomes exceptionally challenging.

A structured ketamine intervention provides a valuable clinical window that enables the veterinary team to:

1. Re-establish a true behavioral baseline by temporarily clearing away the neural "static" of central sensitization.
2. Evaluate which daily pain medications are actively serving the patient and which are simply contributing to systemic toxicity or sedation.
3. Recalibrate and streamline multimodal analgesic dosages with pinpoint accuracy.

Routes of Administration: Matching the Tool to the Setting

Ketamine’s exceptional pharmacological flexibility makes it uniquely suited for palliative care across diverse environments:

• Hospital-Based IV Constant Rate Infusions (CRIs): Ideal for comprehensive clinical resets, oncologic pain management, and rapid stabilization.
• Subcutaneous Infusions: Offers a practical bridge for outpatient or home-based care settings where continuous intravenous access is impractical.
• Intermittent Subcutaneous or Oral/Transmucosal Administrations: Tailored for chronic, long-term management strategies designed to maintain neuroplastic stability at home.

Regardless of the selected route, maintaining subanesthetic dosing parameters is vital. This preserves targeted neuromodulatory and analgesic effects while strictly avoiding the undesirable dissociation, dysphoria, and profound sedation associated with surgical anesthetic doses.

Future Outlook: The Next Frontier in Veterinary Palliative Medicine

As veterinary medicine continues to embrace specialized hospice and palliative care models, the adoption of subanesthetic ketamine is expected to accelerate. Future clinical trajectories point toward standardized outpatient protocols, refined species-specific dosing guidelines—particularly for feline patients—and expanded multimodal formulations combining ketamine with complementary agents like lidocaine and magnesium.

Furthermore, as client education improves, pet owners are increasingly seeking compassionate, advanced options that prioritize comfort and dignity over passive decline. By interrupting the destructive neurological feedback loops of chronic suffering, ketamine empowers veterinary teams to give terminal patients a genuine second wind.

In the landscape of end-of-life care, where time is an invaluable commodity, the ability to reset a patient’s pain experience and restore meaningful quality of life represents a monumental leap forward.